A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Inclusion Criteria: * Histologically confirmed cHL, sALCL, or other CD30-expressing PTCL * Previously treated with brentuximab vedotin containing regimen, with evidence of objective response, and subsequent disease progression or relapse after discontinuing treatment * Documentation of disease relapse or progression ≥6 months after the last dose of brentuximab vedotin * Fluorodeoxyglucose positron emission tomography- (FDG-PET) avid and bidimensional measurable disease of at least 1.5 cm in longest axis as documented by radiographic technique * Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 * Must not be pregnant and, if of childbearing or fathering potential, must agree to use 2 effective contraception methods during study and for 6 months following last dose of study drug Exclusion Criteria: * Previously discontinued brentuximab vedotin due to any Grade 3 or higher toxicity * Existing Grade 2 or higher peripheral neuropathy * Previously refractory to treatment with brentuximab vedotin * History of a cerebral vascular event, unstable angina, or myocardial infarction within 6 months prior to first dose * History of another malignancy within 3 years before first dose of study drug or any evidence of residual disease from previously diagnosed malignancy * Acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for or prophylaxis agent against GvHD * Active cerebral/meningeal disease * Hist…